Last Friday, shares in Tarrytown, New York-based Progenics Pharmaceuticals Inc. ended the session 8.01% higher at $9.57. The stock recorded a trading volume of 956,100 shares. The Company's shares have advanced 12.72% in the last month, 63.03% in the previous three months, and 56.12% since the start of this year. The stock is trading 30.93% above its 50-day moving average and 62.75% above its 200-day moving average. Moreover, shares of Progenics Pharma, which develops medicines for oncology in the US and internationally, have a Relative Strength Index (RSI) of 68.73.
On December 22nd, 2016, Progenics Pharmaceuticals announced that its independent Data Monitoring Committee has completed review of an interim analysis of the Company's ongoing Phase 3 clinical trial of its PSMA-targeted SPECT/CT imaging agent candidate, 99mTc-MIP-1404 (1404), and recommended that the trial continue. The free research report on PGNX is available at:
Boston, Massachusetts-based Tokai Pharmaceuticals Inc.'s stock dropped 11.57%, to close the day at $1.07. A total volume of 2.10 million shares was traded, which was above their three months average volume of 1.35 million shares. The Company's shares have advanced 0.94% in the past month. The stock is trading 5.00% below its 50-day moving average. Additionally, shares of Tokai Pharma, which focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases, have an RSI of 49.28.
On December 22nd, 2016, Tokai Pharmaceuticals and Otic Pharma Ltd, a privately-held, clinical-stage pharma Company announced that the two companies, together with the shareholders of Otic Pharma, have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai. The Company will operate under the name Otic Pharma, Inc. Under terms of the agreement, Otic Pharma's shareholders will receive a total of 32,172,209 shares of newly issued Tokai's common stock, while outstanding Otic Pharma options and convertible securities will be assumed by Tokai. The complimentary report on TKAI can be downloaded at:
Shares in New York headquartered Ophthotech Corp. recorded a trading volume of 2.29 million shares at the close of the last trading session, which was above their three months average volume of 1.90 million shares. The stock ended the day 5.60% higher at $5.09. The Company's shares are trading below their 50-day moving average by 83.01%. Furthermore, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have an RSI of 23.82.
On December 12th, 2016, Ophthotech announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Lucentis® (ranibizumab) anti-VEGF therapy compared to Lucentis® monotherapy for the treatment of wet age-related macular degeneration.
On December 13th, 2016, research firm Goldman upgraded the Company's stock rating from 'Sell' to 'Neutral'. Visit us today and download our complete research report on OPHT for free at:
The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s shares finished Friday's session 6.60% higher at $15.18. A total volume of 1.03 million shares was traded, which was higher than their three months average volume of 614,210 shares. The stock has advanced 14.05% since the start of this year. The Company's shares are trading above their 200-day moving average by 1.15%. Furthermore, shares of Lexicon Pharma, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases, have an RSI of 46.01.
On December 21st, 2016, Lexicon Pharma announced that its pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on optimized insulin therapy. Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had mean A1C reductions from baseline of 0.39% on 200mg once daily sotagliflozin dose (p<0.001) and 0.37% on 400mg once daily sotagliflozin dose (p<0.001) as compared to a reduction of 0.03% on placebo after 24 weeks of treatment, meeting the study's primary endpoint. Get free access to your technical report on LXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA